micvotabart pelidotin
Generic: Micvotabart Pelidotin·Code: MICVO, PYX-201
micvotabart pelidotin: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Pyxis Oncology, Inc. (PYXS) | Phase 1/Phase 2 |
FDA Decisions
FDA_MeetingFDA granted Fast Track Designation to PYX-201 for treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma after progression on platinum-based chemotherapy and an anti-PD-(L)1 antibody.(PYXS)
Frequently asked questions
Who is developing micvotabart pelidotin?
micvotabart pelidotin is being developed by Pyxis Oncology, Inc..
What is micvotabart pelidotin's latest FDA decision?
The most recent tracked FDA decision for micvotabart pelidotin is FDA_Meeting for FDA granted Fast Track Designation to PYX-201 for treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma after progression on platinum-based chemotherapy and an anti-PD-(L)1 antibody., dated February 26, 2025.
Get deeper analysis on micvotabart pelidotin
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis